July 2026 Biopharma Hedge Fund Stock Picks: COGT and 2 More

For July 2026, BPIQ’s Hedge Fund Stock Picks highlight three biopharma companies with different catalyst and risk profiles: Cogent Biosciences and 2 other tickers.

COGT offers a later-stage regulatory setup with two FDA decisions expected 30 days apart. The second pick combines a high-stakes Phase 3 readout with several additional hematology programs. The third pick provides the highest small-cap risk/reward around a dated Phase 3 cardiovascular catalyst.

To qualify as a top hedge fund pick, all three companies are among the more widely held biopharma stocks in BPIQ’s latest hedge fund holdings. COGT and the second pick are each held by 13 funds, while the third pick is held by 10.

Hedge fund ownership does not guarantee that a stock will be a good investment. However, based on more than 20 years of experience investing across different public biopharma strategies, we have found that following leading biopharma hedge fund holdings can be a powerful way to identify companies worth further attention and diligence.

Elite and Apex members get all 3 July 2026 Hedge Fund Stock Picks with downloadable PDF reports.

COGT: The Regulatory-Stage KIT Pick

Cogent Biosciences is the largest and lowest short-term risk among the July 2026 HF Stock Picks with a focus on a validated target, positive Phase 3 data, and two possible FDA approvals in Q4 2026.

The company has:

• Positive pivotal results across systemic mastocytosis and gastrointestinal stromal tumors

• FDA decisions for bezuclastinib in GIST on November 30, 2026, and nonadvanced systemic mastocytosis on December 30, 2026

• A third NDA submitted in advanced systemic mastocytosis

• Approximately $866 million in cash, supporting an estimated runway into late 2028

The key risk is concentration in one molecule. COGT must also navigate two FDA decisions within 30 days while competing with established and advancing KIT inhibitors, including AYVAKIT and elenestinib. But its asset has advantages over these established KIT inhibitors, which yielded a ~$9 billion dollar acquisition in 2025.

Bottom line: COGT may appeal to investors looking for a more validated, mid-cap late regulatory-stage biotech setup with multiple potential approvals ahead this year.

Want All 3 July 2026 Biopharma Hedge Fund Stock Picks?

This Free version includes the overview of COGT pick. The complete July 2026 article, with the full second and third picks and downloadable PDF reports for all three names, is available to BPIQ Elite and Apex members.

Upgrade to Elite or Apex to unlock all 3 June 2026 Hedge Fund Stock Picks!

Final Takeaway

The July 2026 BPIQ HF Stock Picks provide three distinct catalyst profiles.

COGT offers a later-stage regulatory setup aimed at a validated target. The second pick offers a pivotal hematology readout supported by a broader pipeline. The third pick offers concentrated small-cap leverage around a dated Phase 3 event. All three have strong hedge fund support and meaningful upcoming catalysts.

---

This article is not investment, tax, or legal advice. Please do your own diligence and seek advice from professional advisors representing your interests.

Article history:

First published 7/17/26 RF, EJV